APAS Independence sales momentum builds with 3 units invoiced in Q1 FY27
Clever Culture Systems (ASX: CC5) reported 3 APAS® sales completed and fully invoiced in Q1 FY27, with existing customers Novo and AstraZeneca. The company’s 28 October 2026 update also points to an advancing sales pipeline for APAS® Independence, led by global pharmaceutical companies.
The progress underpins expectations for H1 FY27 sales and new evaluations to reach 8 units, matching full-year FY26 (8 units to pharma). If those expectations hold, FY26 volume would be matched in half the time.
Other highlights from the update:
- A new Top-20 global pharmaceutical company is expected to commence a paid APAS® evaluation
- 2 existing global pharmaceutical companies are each expected to progress to a purchase as they finalise their evaluations
- PSC Biotech partnership adds an additional commercial sales channel, including a commitment to purchase an instrument
- Customer insights and advocacy from AstraZeneca and CSL support sales opportunities
- The customer base of large global pharmaceutical companies is expected to broaden to 9
Brent Barnes, CEO and Managing Director
“…While the timing of sales conversion will vary from quarter to quarter, our focus remains on converting evaluations into purchases and supporting broader deployment across customers’ manufacturing networks. This is how we are building a scalable business, growing our global installed base and expanding high-margin, recurring software revenue.”
When big ASX news breaks, our subscribers know first
Pipeline advances across global pharma and a new single-site manufacturer
New Top-20 global pharmaceutical company set to begin paid evaluation
Clever Culture Systems expects to finalise a contract with a new Top-20 global pharmaceutical company to commence a paid evaluation of APAS® Independence in Q2 FY27. Evaluations assess the analytical performance of the instrument and its suitability for potential expansion across a customer’s global drug manufacturing network.
If the evaluation proceeds as expected, 9 pharmaceutical companies will have purchased, commenced paid evaluations of, or be actively evaluating the system. The company describes an expanding customer base as a growing foundation for potential multi-site deployments.
Final procurement talks with two existing global customers
The company is in final procurement discussions with two existing global pharmaceutical customers as they complete their evaluations. Purchase orders are expected during Q2 FY27, and are also expected to be invoiced within the quarter.
These expected sales have the potential to create further opportunities for additional sales across two global networks.
PSC Biotech partnership and single-site purchase commitment
The PSC Biotech partnership adds an additional commercial sales channel, including a commitment to purchase an instrument. It extends market reach into regional and single-site pharmaceutical manufacturers.
Separately, the company is in the final stage of finalising a purchase commitment from a new single-site pharmaceutical manufacturer. Installation and qualification are being planned before the end of the 2026 calendar year.
That sales opportunity originated at the APAS® discovery day held at AstraZeneca in June 2026.
How AI plate reading and the ‘land and expand’ model work
Environmental monitoring culture plates are used in pharmaceutical manufacturing to check for microbial contamination. According to the company, current environmental monitoring processes are manual, with risk of human error and data integrity issues.
APAS® Independence uses artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The company states the technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading.
The ‘land and expand’ strategy starts with a paid evaluation, moves to a purchase, and then aims for potential broader adoption across multiple manufacturing sites. The company links this model to expanding high-margin, recurring software revenue.
The Novo Nordisk reorder of two additional instruments, paired with a custom LIMS integration, moved that customer into formal global validation, the final milestone before potential network-wide deployment.
| Stage | Impact |
|---|---|
| Paid evaluation | Assesses analytical performance and suitability for potential expansion across a customer’s global drug manufacturing network |
| Purchase order | Converts an evaluation into a sale and an installed instrument |
| Multi-site deployment | Potential broader adoption across multiple manufacturing sites |
| Recurring software | Described by management as high-margin, recurring software revenue |
Customer advocacy from AstraZeneca and CSL strengthens the case
Customer insights webinars featured Craig Stephens, Global Head of Quality Control Operations at CSL, and Karen Capper, Global Head of Microbiology, Science, Technology at AstraZeneca. Presenters spoke about their experience with APAS® Independence and their vision of deployment throughout their companies.
Key topics covered included:
- Why patient safety comes first
- Current environmental monitoring processes are manual, with risk of human error and data integrity
- APAS® value proposition delivers fast payback
- Validation strategy is to complete centrally, with a vision to scale across global sites
- Industry adoption for APAS® is building
A five-minute video highlight summary is available online, and the full presentations are on the investor section of the company website. The company says the webinars strengthen market understanding and credibility of its sales strategy.
The CSL Behring lease order, a 5-year all-inclusive arrangement for an instrument at its Broadmeadows facility, shows how an initial evaluation can become a platform assessment across a global manufacturing network.
What happens next for Clever Culture Systems
The company’s expected milestones are outlined below. The announcement notes that risks and uncertainties may result in the delay or termination of sales opportunities, and actual outcomes may differ materially.
- A contract with a new Top-20 global pharmaceutical company is expected to be finalised, with a paid evaluation of APAS® Independence commencing in Q2 FY27.
- Purchase orders from two existing global pharmaceutical customers are expected during Q2 FY27, and are also expected to be invoiced within the quarter.
- Installation and qualification at a new single-site pharmaceutical manufacturer is planned before the end of the 2026 calendar year, with the purchase commitment in its final stage.
- H1 FY27 sales and new evaluations are expected to reach 8 units.
Ready to Learn More About the APAS Independence Sales Pipeline?
Clever Culture Systems has invoiced 3 APAS® units in Q1 FY27 and expects H1 FY27 sales and new evaluations to reach 8 units, matching all of FY26 in half the time. A new Top-20 global pharmaceutical evaluation and two expected purchase orders could broaden its customer base to 9 pharma companies.
Explore the full detail behind the ‘land and expand’ strategy and upcoming milestones by visiting the Clever Culture Systems investor centre. Review the latest announcements and presentations to see how APAS® Independence is positioned for recurring software revenue growth.